^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Clear Cell Renal Cell Carcinoma

    Related cancers:
    3d
    IRF7 is a novel prognostic biomarker in kidney renal clear cell carcinoma. (PubMed, Sci Rep)
    IRF7 is a novel prognostic biomarker in KIRC, influencing tumor immunity and therapy response. Its integration into clinical nomograms could guide precision immunotherapy strategies.
    Journal • IO biomarker
    |
    IRF7 (Interferon Regulatory Factor 7)
    3d
    TMB-related immune gene PAEP influences clear cell renal cell carcinoma progression and prognosis. (PubMed, Eur J Med Res)
    Our study suggests that PAEP may be a potential therapeutic target for ccRCC, providing a new theoretical basis for ccRCC clinical immunotherapy.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • PAEP (Progestagen Associated Endometrial Protein)
    |
    TMB-H • TMB-L
    3d
    NF1/2 mutations predict favorable benefit from immune checkpoint inhibitor-based therapies over VEGFR/mTOR inhibitors in clear cell renal cell carcinoma. (PubMed, Clin Exp Med)
    This tendency was not changed by everolimus (HR = 2.66), but was abrogated slightly by sunitinib (HR = 1.59) and considerably by ICI-based therapies, including nivolumab monotherapy (HR = 1.12), atezolizumab plus bevacizumab (HR = 1.10), and avelumab plus axitinib (HR = 0.69). Overall, our findings suggest that NF1/2 mutations can serve as predictive biomarkers for favorable benefits from ICI-based treatments over VEGFR/mTOR inhibitors in advanced ccRCCs.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    NF1 (Neurofibromin 1)
    |
    EGFR mutation
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • sunitinib • everolimus • Bavencio (avelumab) • axitinib
    4d
    RUBIKID: Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Assistance Publique - Hôpitaux de Paris
    New P2 trial
    4d
    Preclinical evaluation of 68Ga-labeled acetazolamide derivatives as radiotracers targeting carbonic anhydrase IX in clear cell renal cell carcinoma. (PubMed, Eur J Med Chem)
    CAIX specificity was validated by a blocking study in which excess inhibitor reduced tumor uptake by 95 %. These findings identify [68Ga]Ga-14 as a highly promising CAIX-targeted PET tracer for sensitive detection of ccRCC, with potential for future theranostic applications.
    Preclinical • Journal
    |
    CA9 (Carbonic anhydrase 9)
    |
    acetazolamide
    4d
    Immunotherapy in clear cell renal cell carcinoma: current Status, novel Strategies, and future perspectives. (PubMed, Clin Exp Med)
    This review uniquely integrates mechanistic insights with translational advances, providing a forward-looking synthesis of precision immunotherapy in ccRCC. We also emphasize rational combination strategies, biomarker-guided personalization, and irAE management as key priorities to overcome resistance and improve long-term outcomes.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PBRM1 (Polybromo 1) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    6d
    Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=40, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Oct 2025 --> Jul 2025
    Enrollment open • Trial initiation date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Yidafan (ivonescimab)
    6d
    STARLITE 2: Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer (clinicaltrials.gov)
    P2, N=9, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=41 --> 9 | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    CA9 (Carbonic anhydrase 9)
    |
    Opdivo (nivolumab)
    6d
    MUC1/CA15-3 identifies a clear cell renal carcinoma characterized by Sunitinib response with a specific metabolic signature. (PubMed, Clin Exp Med)
    MUC1 expressing ccRCC is a high angiogenic tumor that presents characteristics of increased aggressiveness, and a specific metabolic profile. Serum CA15-3 is a marker of poor survival and predicts response of sunitinib in patients with metastatic disease.
    Journal
    |
    MUC1 (Mucin 1)
    |
    sunitinib
    7d
    GETUG-StORM-01: A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases (clinicaltrials.gov)
    P2, N=77, Recruiting, Centre Francois Baclesse | Trial completion date: Jan 2026 --> Aug 2029 | Trial primary completion date: Sep 2025 --> Apr 2027
    Trial completion date • Trial primary completion date
    7d
    A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive Cancer (clinicaltrials.gov)
    P1, N=20, Completed, Philogen S.p.A. | Recruiting --> Completed
    Trial completion
    7d
    Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial. (PubMed, Nat Med)
    Biomarker data provide proof of mechanism and a potential ccRCC patient selection strategy. ClinicalTrials.gov identifier: NCT04291079 .
    P1 data • Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    Keytruda (pembrolizumab) • linavonkibart (SRK-181)